Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruno Lucidi sold 6,741 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $4.03, for a total value of $27,166.23. Following the completion of the transaction, the director owned 157,237 shares of the company’s stock, valued at $633,665.11. This trade represents a 4.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Bruno Lucidi also recently made the following trade(s):
- On Thursday, November 19th, Bruno Lucidi sold 22,619 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $3.94, for a total value of $89,118.86.
Atea Pharmaceuticals Stock Performance
Atea Pharmaceuticals stock opened at $3.97 on Friday. The business’s 50-day simple moving average is $4.65 and its two-hundred day simple moving average is $4.94. The company has a market cap of $318.81 million, a PE ratio of -2.04 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.92 and a fifty-two week high of $6.45.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.11. As a group, analysts predict that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of Atea Pharmaceuticals during the 2nd quarter worth approximately $33,000. Spark Investment Management LLC acquired a new position in shares of Atea Pharmaceuticals in the 2nd quarter valued at $75,000. Headlands Technologies LLC acquired a new position in shares of Atea Pharmaceuticals in the 2nd quarter valued at $77,000. Engineers Gate Manager LP acquired a new position in shares of Atea Pharmaceuticals in the second quarter worth about $78,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Atea Pharmaceuticals during the 2nd quarter valued at about $82,000. 86.67% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
AVIR has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen upgraded shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Morgan Stanley upped their price objective on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Monday, November 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.00.
Get Our Latest Analysis on Atea Pharmaceuticals
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Recommended Stories
- Five stocks we like better than Atea Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
